Business Wire

MT-UAVIONIX

8.4.2021 03:37:10 CEST | Business Wire | Press release

Share
uAvionix ping200X is the World’s First FAA TSO Certified Drone Transponder

Today, uAvionix, the leader in communications, navigation, and surveillance (CNS) solutions for Unmanned Aircraft Systems (UAS), announced ping200X , its flagship Mode S ADS-B OUT Transponder for UAS, has received Technical Standard Order (TSO) certification from the FAA. ping200X is the pinnacle of years of evolution and investment in groundbreaking, low-Size, Weight, and Power (SWaP) avionics developed by uAvionix – certified for use on civil and defense manned and unmanned aircraft.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210407006039/en/

Weighing only 50 grams, ping200X delivers 200 watts of transmit power while only drawing an average of 1.5 watts from the aircraft's power supply. Its profile enables longer flight times and larger payloads with minimal energy consumption. When paired with truFYX , uAvionix’s SBAS GPS, ping200X meets the requirements of global controlled airspace, delivering safe separation information to Air Traffic Control (ATC), Traffic Collision Avoidance Systems (TCAS), and Detect and Avoid (DAA) systems.

ADS-B and transponder technology is a key component of UAS integration for mixed-use airspace. The FAA’s recent ruling on remote identification for UAVs establishes that Part 21 certificated aircraft must be equipped with a Remote ID device and/or ADS-B OUT Transponder for legal operations. Additionally, the FAA's Concept of Operations for Upper-Class E Traffic Management (ETM) includes ADS-B and Mode S Transponders as key technologies enabling coordination in the upper atmosphere.

ping200X integrates and combines a Mode S Transponder, ADS-B OUT, and an altitude encoder certified to the following TSOs:

  • TSO-C112e (Mode S Transponder)
  • TSO-C166b (ADS-B OUT Extended Squitter)
  • TSO-C88b (altitude encoder)

“Certified avionics ensure the systems perform to the same high standards that have allowed aviation to remain the safest form of transportation for decades,” said Christian Ramsey, President. “This is even more important for systems like transponders and ADS-B which interact with other airspace users. Regulators and ANSPs demand the design assurance and quality assurance that a TSO offers to ensure safe separation of aircraft.”

The ping200X is integrable with many popular onboard UAS autopilots for dynamic control from ground control stations (GCS). ping200X can also be pre-configured before flight and carried as a payload. Replicating the functionality of a cockpit transponder controller, the uAvionix mini-controller allows you to dial-in a squawk code before takeoff for even quicker integration and rapid deployment.

To learn more about ping200X or to request a quote, visit uAvionix.com/products/ping200X/ .

Link:

ClickThru

Social Media:

https://www.facebook.com/uavionix

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release

MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye